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OBJECTIVES: To describe the use of biologics, in the treatment of rheumatoid 
arthritis (RA), in a real life Canadian setting. METHODS: Patients covered by the 
Quebec provincial drug reimbursement program (RAMQ) who had a diagnosis of 
RA and had used at least one biologic in the period from January 1, 2001 to June 
30, 2011 were selected. Agents included in the study were adalimumab, 
etanercept, infliximab, abatacept, anakinra, golimumab, rituximab, tocilizumab 
and ustekinumab, as they were all reimbursed by the drug program. The use of 
biologics was analyzed in terms of patient characteristics, treatment patterns 
and costs. RESULTS: A total of 4225 patients were included in this study. The 
average age was 51.1 years (SD=14.6), and there was a higher proportion of 
women (69.9%). About two-thirds of patients (63.3%) had only a diagnosis of RA, 
while 36.7% had two or more concomitant diagnoses, such as psoriasis (15.9%) 
and psoriatic arthritis (11.5%). During the course of the study period, most 
patients used only one biologic (78.3%). The number of biologic scripts increased 
by an annual rate of 25% over the last 5 years; from 12,926 scripts in 2006 to 
26,491 in 2010. Out of the total 135,616 scripts for a biologic, 74,058 were for 
etanercept (54.6%), 27,994 for adalimumab (25.9%), and 23,858 for infliximab 
(17.6%). Concomitant use of methotrexate decreased over time from 60.3% in the 
first year following initiation of the biologics to 44.2% in the fourth year. Average 
annual cost for biologics was $17,040 per patient and did not vary significantly 
over time. CONCLUSIONS: RA is a complex disease. More than a third of the 
patients studied had concomitant inflammatory diseases. Biologics use 
increased over time, and there was a marked reduction in the use of 
concomitant methotrexate four years after biologic initiation.  
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PRS1  
INHALED CORTICOSTEROID (ICS) USE IN NURSING HOME (NH) RESIDENTS 
WITH COPD  
Zarowitz BJ1, O'Shea T2 
1Omnicare, Inc., Cincinnati, OH, USA, 2Omnicare, Inc., Englewood, OH, USA  
OBJECTIVES: The prevalence of COPD in NH residents is 10-20%. While ICS use 
occurs commonly, there are concerns about adverse consequences of therapy. 
Our goal was to develop a profile of NH residents with COPD, and to identify 
differences in outcome markers in residents receiving ICS versus those not 
receiving ICS. METHODS: Pharmacy claims and Minimum Data Set (MDS) 2.0 
data from January 1, 2009 to September 30, 2009 and October 1, 2009 to 
September 3, 2010 were extracted from Omnicare Senior Health Outcomes, then 
linked and de-identified. A profile of residents with COPD was developed using 
descriptive analyses. Residents receiving ICS were matched to residents not 
receiving ICS on age, gender, tobacco use, and prevalence of diabetes mellitus, 
respiratory infection, osteoporosis, pneumonia, hip fracture, and “other” 
fracture. One year change from baseline within subsets was assessed using Chi-
square analyses primarily. Linear logistic regression was used to compare 
baseline-adjusted outcomes between subsets. RESULTS: Fifty-nine percent of NH 
residents with COPD had full MDS and pharmacy data available (24,733/41,598). 
Of these, 4000 ICS-receiving and 4000 non-ICS-receiving residents were matched. 
The ICS subset generally showed higher cognition, memory, and functioning (all 
p=0.001) comparatively. The non-ICS subset demonstrated higher incidence of 
Alzheimer’s disease, other dementia, and greater cognitive impairment (all 
p=0.001), while shortness of breath, anxiety, glaucoma, pneumonia, oxygen 
therapy, and at least 1 hospital stay were more common in the ICS subset (all 
p<0.05). The 1 year change in ICS subset showed a significant increase in the 
adjusted odds ratio of “other” fracture (non-hip) when compared to the non-ICS 
subset {OR 1.44 [1.07, 1.94], p=0.016)}. CONCLUSIONS: Our analysis indicates NH 
residents with COPD receiving ICS may be at greater risk of non-hip fracture. 
Research focusing on a longer-term horizon, duration of ICS treatment, and 
recommended use of ICS is needed to further understand the consequences of 
ICS use.  
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LONG-ACTING BETA-AGONISTS AND ASTHMA EXACERBATIONS REQUIRING 
SHORT COURSES OF ORAL CORTICOSTEROIDS: A MULTI-CATEGORY EXPOSURE 
MARGINAL STRUCTURAL MODELS ANALYSIS  
Ali AK1, Hartzema AG2, Hendeles L2, Lu X2, Winterstein AG2, Segal R2 
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OBJECTIVES: To evaluate asthma-related morbidity in patients exposed to long-
acting beta-agonist (LABA) bronchodilators as monotherapy, inhaled 
corticosteroids (ICS) monotherapy, and ICS/LABA combination therapy. 
METHODS: The Clinical Practice Research Datalink (formerly the General Practice 
Research Database, GPRD) was used to apply marginal structural models for the 
evaluation of asthma-related morbidity measured by prescriptions for short 
courses oral corticosteroids (OCS) within 12 months of initiating LABA, ICS, or 
ICS/LABA in a cohort of asthamtic adults. Asthma severity was measured by the 
following variables during 12 months before LABA initiation (prescription for 
OCS, asthma-related visits to hospitals or emergency departments, and number 
of prescriptions for inhaled short-acting beta-agonists [SABA]); and the following 
variables at the initiation and during 12 months after (prescription for SABA, and 
number of asthma drug classes prescribed). RESULTS: A total of 51,103 asthmatic 
adults were followed for 12 months after receiving first prescription for study 
drugs from January 4, 1993 to August 20, 2010. About 92% initiated ICS 
monotherapy, 1% initiated LABA monotherapy, and 7% initiated combination 
therapy. Among ICS/LABA combination therapy initiators, 78% were in single-
device formulations and 22% were in separate-devices. Compared with ICS 
monotherapy, LABA monotherapy is associated with 10% increased risks of 
asthma exacerbations requiring short courses of OCS (HR, 1.10; 95%CI, 1.07-1.18). 
Initiators of ICS/LABA combination therapy are respectively 62% and 50% less 
likely to receive prescriptions of OCS for asthma exacerbations than initiators of 
ICS (HR, 0.38; 95%CI, 0.12-0.66) or LABA monotherapies (HR, 0.50; 95%CI, 0.14-
0.78). CONCLUSIONS: Inhaled LABA should not be prescribed as monotherapy to 
adults with asthma, and should be uased as an add-on to ICS as maintenance 
therapy. The findings suggest presence of time-dependent confounding by 
asthma severity in the assessment of LABA association with asthma 
exacerbations requiring prescriptions of OCS.  
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DISEASE BURDEN OF IDIOPATHIC CHRONIC COUGH (ICC) AND CHRONIC 
COUGH (CC) IN COPD, IPF AND LUNG CANCER (LC): AN EXPLORATORY 
LITERATURE REVIEW  
Gonzalez McQuire S1, Kucmin-Bemelmans I2, Hensen M2 
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OBJECTIVES: Chronic cough (CC) accounts for 10–38% of all referrals to 
respiratory physicians (Morice, 2007). Some patients suffer CC related to lung 
cancer (LC), chronic obstructive pulmonary disease (COPD) and idiopathic 
pulmonary fibrosis (IPF). Additionally a proportion of patients with CC with no 
explanatory etiology remains symptomatic despite treatment and is classified as 
suffering idiopathic chronic cough (ICC). To understand the burden of CC and 
ICC, a systematic literature search was conducted on the epidemiology, natural 
history, humanistic and economic burden. METHODS: A systematic search 
strategy was implemented in MEDLINE, EMBASE, Cochrane HTA and NHS Centre 
for Review and Dissemination databases to identify relevant English language 
publications on the burden of cough since 2002. RESULTS: 1447 publications 
were identified in the search and an additional 10 from bibliographic review. Of 
these 98 articles were selected for further review using pre-defined inclusion 
criteria. The reported prevalence of CC varies between countries (9 to 33%); very 
limited information on CC in LC, COPD, IPF and ICC was found. Prolonged 
hypersensitivity of the cough reflex has been proposed as a mechanism, partly 
explaining resistance to treatment of CC and ICC. Patients’ quality of life 
deteriorates due to insomnia, urinary incontinence, social disability or 
depression. Only one economic evaluation investigating the cost effectiveness of 
managing CC of unknown etiology was identified. It demonstrated that empirical 
treatment is the cheapest management option for CC, while cough management 
involving diagnostic procedures recommended by American College Chest 
Physicians is the most expensive option. CONCLUSIONS: The published 
literature on CC and ICC is extremely limited. Further research is needed to 
understand the humanistic and economic burden of these conditions and 
implement proper disease assessment. However, appropriate diagnosis  
and management of ICC and CC in COPD, IPF and LC create a significant unmet 
need.  
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OBJECTIVES: The impact of macitentan, a novel endothelin receptor antagonist, 
on PAH-related hospitalizations was evaluated in the SERAPHIN trial 
(NCT00660179). METHODS: PAH patients aged ≥12 years in WHO functional class 
(FC) II-IV were randomized 1:1:1 to oral macitentan 3 or 10mg, or placebo once-
daily. Time to either death due to PAH or hospitalization for PAH up to end  
of treatment (EOT), a secondary endpoint, and time to hospitalization for PAH up 
to EOT were evaluated via Cox proportional hazards regression and log rank 
tests. Annual rates of PAH-related hospitalizations and inpatient hospital days 
up to EOT (pharmacoeconomic endpoints) were adjusted post hoc using negative 
binomial regression for baseline FC (I/II vs. III/IV) and 6-minute walk distance 
(>380 vs ≤380 m). RESULTS: The 742 patients (76% female, median age 45 [range 
12-85] years) were mostly in FC II (52%) or III (46%). Median treatment duration 
was >2 years. Risk of death due to PAH or hospitalization for PAH was reduced by 
33% with macitentan 3mg (HR 0.67, 97.5% CI 0.46-0.97, P=0.0146) and 50% with 
macitentan 10mg (HR 0.50, CI 0.33-0.75, P<0.0001) versus placebo. Risk of 
hospitalization for PAH was reduced by 39% with macitentan 3mg (HR 0.61,  
CI 0.42-0.90, P=0.0040) and 50% with macitentan 10mg (HR 0.50, CI 0.34-0.76, 
P=0.0001). Of the patients randomized to placebo, macitentan 3mg and 10mg, 
33% (n=82), 24% (n=59), and 21% (n=50), respectively, had ≥1 hospitalization  
for PAH. Annual rates of PAH-related hospitalizations and inpatient hospital 
days were reduced by 43% (treatment-effect ratio [TER] 0.57, 95% CI 0.38-0.86, 
P=0.0068) and 33% (TER 0.67, CI 0.33-1.37, P=0.2707), respectively,  
with macitentan 3mg, and by 55% (TER 0.45, CI 0.30-0.69, P=0.0002) and 52% (TER 
0.48, CI 0.24-0.97, P=0.0416), respectively, with macitentan 10mg versus  
placebo. CONCLUSIONS: Significant reductions in these hospitalization 
endpoints demonstrate that macitentan improves long-term PAH-related health 
outcomes.  
